A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat’s Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia
American Journal of Nephrology · 05.03.2026 · 1-11
DOI: 10.1159/000551113 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 05.03.2026. Verfasst von Jie Ma und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
This phase III trial assessed desidustat’s efficacy and safety compared with placebo for the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD).
Methods
A multicenter, randomized, double-blind trial enrolled 152 NDD-CKD patients with anemia (101 desidustat, 51 placebo). Primary endpoint: hemoglobin (Hb) change from baseline to weeks 7–9. Secondary endpoints included Hb response rate (≥100 g/L), time to target Hb, and target Hb maintenance (100–120 g/L). Safety evaluated treatment-emergent adverse events (TEAEs). Exploratory endpoints analyzed Hb dynamics (weeks 21–25) and serum hepcidin levels (baseline-week 53).
Results
After 9 weeks of treatment, desidustat increased Hb level from 89.18 g/L to 105.66 g/L, whereas placebo decreased from 89.41 g/L to 88.51 g/L, with a mean difference of 17.52 g/L (95% confidence interval [CI]: 14.35–20.68) in the full analysis set. And in the per protocol set, desidustat increased Hb level from 88.86 g/L to 105.62 g/L, and placebo declined from 89.37 g/L to 87.57 g/L, with a mean difference of 18.39 g/L (95% CI: 15.39–21.39). Hb response rates were 85.15% vs. 23.53% (p < 0.001). Median time to target Hb was 30 days with desidustat vs. 0 days with placebo (p < 0.001). By week 9, desidustat maintained Hb within target range 51.68% of the time vs. 10.24% for placebo (p < 0.001). TEAE incidence was comparable between groups. During weeks 21–25, Hb rose further (desidustat: +21.26 g/L; placebo: +26.63 g/L). Serum hepcidin decreased sharply in desidustat by week 9 (−67.43 ng/mL vs. −6.38 ng/mL; placebo), though placebo showed delayed reduction by week 25 – levels equalized by week 53.
Conclusion
Desidustat significantly improved Hb levels and accelerated anemia correction in NDD-CKD patients versus placebo, with comparable safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Nephropathy, Qilu Hospital of Shandong University, Cheeloo Medical College, Shandong University, Jinan, China.
- Department of Nephrology, First People's Hospital of Tancheng, Linyi, China.
- Department of Nephrology, Taihe Hospital, Shiyan, China.
- Department of Nephrology, The First Affiliated Hospitals of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China.
- Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Zitieren
APA
Ma, J., Yang, X., Xiao, X., Sun, C., Zhang, Q., Wang, C., Xu, Y., Zhao, J., Yang, A., Cheng, H., Chen, M., Chen, W., Zheng, Z., Shi, Y., Zhao, Z., Yang, Z., Yang, L., Yao, L., Zhong, X., …, & Li, X. (2026). A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat’s Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia. American Journal of Nephrology, 1-11. https://doi.org/10.1159/000551113
Vancouver
Ma J, Yang X, Xiao X, Sun C, Zhang Q, Wang C, et al. A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat’s Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia. American Journal of Nephrology. 2026:1-11. doi:10.1159/000551113
BibTeX
@article{Ma2026,
author = {Ma, Jie and Yang, Xiangdong and Xiao, Xiaoyan and Sun, Changyou and Zhang, Qinghong and Wang, Caili and Xu, Yan and Zhao, Jianrong and Yang, Aicheng and Cheng, Hong and Chen, Menghua and Chen, Wenli and Zheng, Zhihua and Shi, Yongjun and Zhao, Zhanzheng and Yang, Zhenhua and Yang, Lin and Yao, Li and Zhong, Xiaoshi and Deng, Yilan and Xiong, Zuying and Yang, Xiaoping and Zhang, Chunjiang and Xie, Weiji and Yin, Aiping and Zhou, Hua and Bi, Weihong and Li, Wenbin and Wang, Junxia and Li, Suhua and Yin, Yuanyuan and Li, Xuemei},
title = {A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat’s Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia},
journal = {American Journal of Nephrology},
year = {2026},
pages = {1--11},
doi = {10.1159/000551113}
}
EUVIMED